Central nervous system , drug

The application of nonlinear dynamics to brain electrical activity offered new information about the dynamics of the underlying neuronal networks and formulated the brain disorders on the basis of qualitatively different dynamics [479]. 

Serotonin plays an active role in temperature regulation and in particular in the maintenance of the body s set point [543-545]. More recently, numerous pharmacological studies have suggested the involvement of homeostatic control mechanisms [544, 546] that are achieved through interplay between the 5-hydroxytryptamine (HT)1A and 5-HT2A/C receptor systems [545,547,548]. Administration of a 5-HTlA-receptor agonist that is used therapeutically as an antidepressant and antianxiety drug causes hypothermia [549,550]. 

So far, only very few of these models incorporate complex regulatory behavior [534,551,552], Specifically, no mathematical models have been developed to characterize the complex time behavior of the hypothermic response in a strict quantitative manner, and neither attempts to link existing temperature regulation models [553] to pharmacokinetic models describing the time course of the drug concentration in the body. 

To characterize 5-HTlA-agonist-induced hypothermia, Zuideveld et al. [554] developed a mathematical model that describes the hypothermic effect on the basis of the concept of a set point and a general physiological response model [431,555]. The model was applied to characterize hypothermic response vs. time profiles after administration of different doses of the reference 5-HT1A receptor agonists R- and S-8-OH-DPAT. 

The classical three-compartment model describes pharmacokinetics of 5-HT1A receptor agonists. By means of a sigmoidal function E (c), the 5-HT1A agonist concentration c (t) influences the set-point signal that dynamically interacts with the body temperature. By using x (t) and y (t) as dimensionless state variables for the set-point and temperature, respectively, the model is expressed by the set of two nonlinear differential equations  

---

Drugs Central nervous system drugs - Anesthetic gases... 

Neubig, R. R., and Siderovski, D. P. (2002). Regulators of G-protein signaling as new central nervous system drug targets. Nature Rev. Drug Disc. 1 187—196. 

D. A., Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab. Dispos. 2005, 33, 175-181. 

K., Steiner, I Baumgartner, C. and Muller, M. (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics, 78, 182-190. 

Catecholamines, 6 (1969) 200 Cell membrane transfer, 14(1977) 1 Central nervous system, drugs, transmitters and peptides, 23 (1986) 91 Centrally acting dopamine D2 receptor agonists, 29 (1992) 185 Chartreusin, 19 (1982) 249 Chelating agents, 20 (1983) 225... 

Benzodiazepine derivates, seven-membered rings with 2 N atoms in 1,4 position are the pivotal structures of the benzodiazepine class of breakthrough CNS (central nervous system) drugs such as Librium and Valium. The most recent drug in this class, Sepracor s Lunesta (eszopiclone), is composed almost entirely of A-heterocyclics. Like most modern drugs, esczopi-clone also has a chiral center ... 

CENTRAL NERVOUS SYSTEM DRUGS Sedative-Hypnotics... 

More important than numerical data are the clinical implications of differences between the two countries. The largest differences have narrowed since the previous study, but important categories in which the U.S. still lagged behind Britain in December 1976 included cardiovascular drugs, peptic ulcer treatment, and central nervous system drugs—including therapies for depression, epilepsy, and migraine. 

DNLM 1. Mental Disorders—drug therapy. 2. Central Nervous System—drug effects. 

Cell-Mediated Central Nervous System Drug Delivery.602... 

VI. Central Nervous System Drugs, Sedation, and Driving... 

Pajouhesh, H. Lenz, G. R. Medicinal Chemical Properties of Successful Central Nervous System Drugs. NeunoRx... 

Peripheral and Central Nervous System Drugs Advisory Committee... 

Cardiovascular or central nervous system drug toxicity Accidental perforation or explosion of the globe Retained intraorbital needle fragment... 

Neubig RR, Siderovski DP. Regulators of G-protein signalling as 23. new central nervous system drug targets. Nat. Rev. Drug Discov. 2002 1 187-197. 

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17 1897-1906. 

---